
Results
15
Companies which are more than 50% undervalued based on analyst price target.
15 companies
Inventiva
Market Cap: €773.8m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.42
7D
11.4%
1Y
30.3%
Valneva
Market Cap: €425.8m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.34
7D
4.7%
1Y
-5.8%
Cellectis
Market Cap: €206.9m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.85
7D
16.4%
1Y
104.0%
Innate Pharma
Market Cap: €150.1m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.66
7D
5.6%
1Y
9.0%
Sensorion
Market Cap: €130.5m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
10.9%
1Y
-27.0%
Adocia
Market Cap: €83.7m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€4.45
7D
5.3%
1Y
17.8%
OSE Immunotherapeutics
Market Cap: €73.9m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.73
7D
18.7%
1Y
-27.1%
ABIONYX Pharma
Market Cap: €71.6m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€2.08
7D
2.0%
1Y
72.2%
AB Science
Market Cap: €58.7m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.77
7D
-11.6%
1Y
-52.5%
MaaT Pharma
Market Cap: €49.7m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.88
7D
13.8%
1Y
-45.0%
THX Pharma Société Anonyme
Market Cap: €45.7m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.68
7D
16.8%
1Y
211.9%
Nicox
Market Cap: €33.4m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
3.5%
1Y
71.6%
Valbiotis
Market Cap: €19.5m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.85
7D
14.1%
1Y
-1.4%
GenSight Biologics
Market Cap: €18.8m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.083
7D
3.4%
1Y
-45.2%
Advicenne
Market Cap: €18.1m
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.
ALDVI
€1.40
7D
30.8%
1Y
4.2%